CU20100008A7 - Estratrienos 8-beta sustituidos como estrógenos de acción selectiva - Google Patents

Estratrienos 8-beta sustituidos como estrógenos de acción selectiva

Info

Publication number
CU20100008A7
CU20100008A7 CUP2010000008A CU20100008A CU20100008A7 CU 20100008 A7 CU20100008 A7 CU 20100008A7 CU P2010000008 A CUP2010000008 A CU P2010000008A CU 20100008 A CU20100008 A CU 20100008A CU 20100008 A7 CU20100008 A7 CU 20100008A7
Authority
CU
Cuba
Prior art keywords
stratriens
strateges
selective action
preparations
beta
Prior art date
Application number
CUP2010000008A
Other languages
English (en)
Other versions
CU23885B1 (es
Inventor
Ina Thieme
Nico Braeuer
Katja Prelle
Olaf Peters
Hans-Peter Muhn
Karl-Heinrich Fritzemeier
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20100008A7 publication Critical patent/CU20100008A7/es
Publication of CU23885B1 publication Critical patent/CU23885B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de estra-1,3,5(10)-trieno 8beta-sustituidos de fórmula general I ESPACIO PARA LA FÓRMULA su uso como ingredientes farmacéuticos activos que tienen una mayor afinidad in vitro por preparaciones de receptores de estrógeno de próstata de rata que por preparaciones de receptores de estrógeno de útero de rata, y que presentan una acción preferencial in vivo en el ovario en comparación con el útero, con su producción, su uso terapéutico, y con formas de administración que contienen los nuevos compuestos.
CU20100008A 2007-07-12 2010-01-12 Estratrienos 8-beta sustituidos como estrógenos de acción selectiva CU23885B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (en) 2007-07-12 2007-07-12 8-beta-substituted estratrienes as selectively active estrogens
PCT/EP2008/059115 WO2009007454A2 (en) 2007-07-12 2008-07-11 8-beta-substituted estratrienes as selectively active estrogens

Publications (2)

Publication Number Publication Date
CU20100008A7 true CU20100008A7 (es) 2011-05-27
CU23885B1 CU23885B1 (es) 2013-04-19

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100008A CU23885B1 (es) 2007-07-12 2010-01-12 Estratrienos 8-beta sustituidos como estrógenos de acción selectiva

Country Status (34)

Country Link
US (1) US20090029957A1 (es)
EP (2) EP2014672A1 (es)
JP (1) JP2010533152A (es)
KR (1) KR20100037593A (es)
CN (1) CN101687902B (es)
AR (1) AR067507A1 (es)
AU (1) AU2008274198A1 (es)
BR (1) BRPI0814207A2 (es)
CA (1) CA2692727A1 (es)
CL (1) CL2008002027A1 (es)
CO (1) CO6270230A2 (es)
CR (1) CR11211A (es)
CU (1) CU23885B1 (es)
CY (1) CY1113351T1 (es)
DK (1) DK2176282T3 (es)
DO (1) DOP2010000017A (es)
EA (1) EA017124B1 (es)
EC (1) ECSP109872A (es)
ES (1) ES2393942T3 (es)
HN (1) HN2010000081A (es)
HR (1) HRP20120952T1 (es)
MA (1) MA31565B1 (es)
NZ (1) NZ582490A (es)
PA (1) PA8789401A1 (es)
PE (1) PE20090825A1 (es)
PL (1) PL2176282T3 (es)
PT (1) PT2176282E (es)
RS (1) RS52541B (es)
SI (1) SI2176282T1 (es)
TN (1) TN2010000007A1 (es)
TW (1) TW200911824A (es)
UA (1) UA99918C2 (es)
UY (1) UY31220A1 (es)
WO (1) WO2009007454A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
US10744439B2 (en) * 2016-06-24 2020-08-18 K&N Engineering, Inc. Compound air filter and method of removing airborne molecular contaminants and volatile organic compounds therefrom
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
HN2010000081A (es) 2013-07-01
HRP20120952T1 (hr) 2012-12-31
TW200911824A (en) 2009-03-16
CR11211A (es) 2010-04-27
SI2176282T1 (sl) 2013-02-28
MA31565B1 (fr) 2010-08-02
CA2692727A1 (en) 2009-01-15
WO2009007454A3 (en) 2009-03-05
DK2176282T3 (da) 2012-12-03
EA201000097A1 (ru) 2010-08-30
UA99918C2 (ru) 2012-10-25
BRPI0814207A2 (pt) 2015-01-27
US20090029957A1 (en) 2009-01-29
AR067507A1 (es) 2009-10-14
CN101687902A (zh) 2010-03-31
CY1113351T1 (el) 2016-06-22
UY31220A1 (es) 2009-03-02
JP2010533152A (ja) 2010-10-21
RS52541B (sr) 2013-04-30
CL2008002027A1 (es) 2009-01-16
AU2008274198A1 (en) 2009-01-15
PL2176282T3 (pl) 2013-06-28
ECSP109872A (es) 2010-02-26
CO6270230A2 (es) 2011-04-20
WO2009007454A2 (en) 2009-01-15
EP2176282A2 (en) 2010-04-21
CU23885B1 (es) 2013-04-19
CN101687902B (zh) 2013-07-24
NZ582490A (en) 2012-03-30
PT2176282E (pt) 2012-11-30
ES2393942T3 (es) 2013-01-02
EP2014672A1 (en) 2009-01-14
PA8789401A1 (es) 2009-04-23
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
EP2176282B1 (en) 2012-08-22
PE20090825A1 (es) 2009-07-25
EA017124B1 (ru) 2012-10-30
DOP2010000017A (es) 2010-01-31

Similar Documents

Publication Publication Date Title
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
NI201500106A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno.
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
CR11802A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
GT201000153A (es) Agonistas novedosos de los receptores de glucocorticoides
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
UY31922A (es) Compuestos
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
SV2009003168A (es) Derivados de oxazolidona como moduladores pr
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
UY28911A1 (es) Profármacos de esteroides con acción androgénica
CL2008002289A1 (es) Compuestos derivados de n-heteroaril-carboxamidas triciclicas; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar dolor, inflamacion, trastornos metabolicos, trastornos urologicos, entre otros.
UY31428A1 (es) Derivados 1,2,4-triazol tiofeno fusionados como moduladores de mglur5
UA108865C2 (uk) Парентеральна фармацевтична композиція у вигляді суспензії уповільненого вивільнення, у низькій та наднизькій дозованій формі, у гормональній терапії при клімактеричному синдромі
UY33393A (es) Una composición farmacéutica de liberación controlada de losartan
UY29625A1 (es) Uso de moduladores no esteroides de receptores de progesterona
ECSP11011501A (es) 17 -alquil-17 -oxi-estratrienos
GT200600271A (es) Moduladores no esterides de receptores de progesterona

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)